Foster City, CA, May 5, 2009 – Jim Neal is appointed as Acting President and Acting Chief Executive Officer. In addition, the Company announces that it is in advanced negotiations with candidates for the position of Acting Chief Financial Officer. The Company also announced the appointment of Julie Thomas Goggin as its General Counsel and Corporate Secretary.

Jim Neal was most recently Entelos’ Chief Business Officer, and prior to that was the Chief Executive Officer of Iconix Biosciences, Inc., a company acquired by Entelos in 2007. Julie Thomas Goggin was most recently the Company’s General Counsel. In addition, Entelos announces the departure of James Karis, the Company’s former Chief Executive Officer and Alan Blazei, the Company’s former Chief Financial Officer and Company Secretary.

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, “virtual human” technology, and toxicology reference systems to develop safer and more effective drugs, improve the quality of health-related consumer products, and deliver on the promise of personalized medicine. Entelos provides customized products, technology and research services to global pharmaceutical, health-care, and consumer products companies in safety testing, arthritis, cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal care products.